



## Corrigendum

**Corrigendum to “ZY0511, a novel, potent and selective LSD1 inhibitor, exhibits anticancer activity against solid tumors via the DDIT4/mTOR pathway” [Cancer Lett. 454 (2019) 179–190]**

Yan Li<sup>a</sup>, Lei Tao<sup>a</sup>, Zeping Zuo<sup>a</sup>, Yang Zhou<sup>b</sup>, Xinying Qian<sup>a</sup>, Yiyun Lin<sup>a</sup>, Hui Jie<sup>a</sup>, Chunqi Liu<sup>a</sup>, Zhuoling Li<sup>a</sup>, Huaqin Zhang<sup>a</sup>, Hu Zhang<sup>c</sup>, Xiaobo Cen<sup>d</sup>, Shengyong Yang<sup>a,\*\*</sup>, Yinglan Zhao<sup>a,\*</sup>

<sup>a</sup> State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, 610041, China

<sup>b</sup> Chengdu Institute of Organic Chemistry, Chinese Academy of Sciences, Chengdu, 610041, China

<sup>c</sup> Department of Gastroenterology, West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, China

<sup>d</sup> National Chengdu Center for Safety Evaluation of Drugs, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China

The authors regret we found the wrong marking in Figure 2B that the control group and ZY0511 treated group were reversed. The corrected Figure 2 and the legend of Figure 2 along with the figure itself are shown herein.


DOI of original article: <https://doi.org/10.1016/j.canlet.2019.03.052>

\* Corresponding author. State Key Laboratory of Biotherapy and Cancer Centre, West China Hospital, West China Medical School, Sichuan University, #17, 3rd Section, Ren min South Road, Chengdu, 610041, China.

\*\* Corresponding author. State Key Laboratory of Biotherapy and Cancer Centre, West China Hospital, West China Medical School, Sichuan University, #17, 3rd Section, Ren min South Road, Chengdu, 610041, China.

E-mail addresses: [yangsy@scu.edu.cn](mailto:yangsy@scu.edu.cn) (S. Yang), [zhaoyinglan@scu.edu.cn](mailto:zhaoyinglan@scu.edu.cn) (Y. Zhao).

<https://doi.org/10.1016/j.canlet.2019.05.002>



**Fig. 2.** Gene expression changes induced by ZY0511 in cancer cells.

(A) The volcano plot of the mRNA-seq analysis of HeLa cells after ZY0511 exposure (red represents upregulation, blue represents downregulation, and gray represents no meaningful change). (B) Representative genes expression in the HeLa cells after ZY0511 exposure. (C) Representative GO term analysis of upregulated genes after ZY0511 exposure. (D) Representative GO term analysis of downregulated genes after ZY0511 exposure. (E) The qPCR validation of mRNA-seq genes expression in the HeLa and HCT116 cells. (F) Western blot detection of DDIT4 and mTOR signaling-related proteins in cancer cells after ZY0511 treatment;  $\beta$ -actin was used as the reference protein. (G) Immunofluorescence detection of DDIT4 in cancer cells after ZY0511 treatment; Hoechst was used to stain the nuclei.

The authors would like to apologise for any inconvenience caused.